LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-7. (Canceled)

8. (Currently Amended) The method of claim 25, wherein said antisense oligonucleotide is a chimeric antisense oligonucleotide.

9.-13. (Canceled)

14. (Currently Amended) The method of claim 25, wherein said antisense oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase.

15. (Currently Amended) The method of claim 14, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

16. (Currently Amended) The method of claim 14, wherein said modified internucleoside linkage is phosphorothioate internucleoside linkage.

17. (Currently Amended) The method of claim 14, wherein said modified nucleobase is a 5-methylcytosine.

18.-24. (Canceled)

25. (Currently Amended) A method of inhibiting the expression of apolipoprotein(a) in a cell or tissue *in vivo*, said method comprising contacting said cell or tissue with an antisense oligonucleotide 12 to 30 nucleobases in length targeted to SEQ ID NO: 4, wherein said antisense oligonucleotide comprises at least 8 consecutive nucleobases of SEQ ID NO: 23 and is 100% complementary to SEQ ID NO: 4, thereby inhibiting the expression of apolipoprotein(a) ~~does not substantially inhibit plasminogen, and wherein said antisense oligonucleotide inhibits the expression of apolipoprotein(a) mRNA by at least 10%~~.

26.-29. (Canceled)

30. (Currently Amended) A method of treating a human having a disease or condition treatable by the reduction of apolipoprotein(a), said method comprising

selecting a human having elevated plasma lipoprotein(a) levels; and

administering to said human a therapeutically effective amount of an antisense oligonucleotide 12 to 30 nucleobases in length targeted to SEQ ID NO: 4, wherein said antisense oligonucleotide comprises at least 8 consecutive nucleobases of SEQ ID NO: 23 and is 100% complementary to SEQ ID NO: 4 ~~does not substantially inhibit plasminogen, and wherein said antisense oligonucleotide inhibits the expression of apolipoprotein(a) mRNA by at least 10%~~.

31. (Canceled)

32. (Currently Amended) The method of claim 30, wherein the disease or condition is ~~a cardiovascular disorder,~~ atherosclerosis[[,]] or ~~hypercholesterolimia~~ hypercholesterolemia~~,~~ ~~coronary artery disease or any combination thereof~~.

33.-51. (Canceled)

52. (Currently Amended) The method of claim 30, wherein said antisense oligonucleotide is a chimeric antisense oligonucleotide.

53. (Currently Amended) The method of claim 30, wherein said antisense oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase.

54. (Currently Amended) The method of claim 53, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

55. (Currently Amended) The method of claim 53, wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.

56. (Currently Amended) The method of claim 53, wherein said modified nucleobase is a 5-methylcytosine.

57.-58. (Canceled)

59. (Currently Amended) The method of claim 30, further comprising measuring

lipoprotein(a) levels in the serum of said ~~patient~~ human following said administering.

60. (New) The method of claim 8, wherein said chimeric antisense oligonucleotide comprises a gap segment of ten 2'-deoxynucleotides positioned between 5' and 3' wing segments of five 2'-O-methoxyethyl modified nucleosides.

61. (New) The method of claim 60, wherein each internucleoside linkage of said chimeric antisense oligonucleotide is a phosphorothioate internucleoside linkage.

62. (New) The method of claim 61, wherein each cytosine of said chimeric antisense oligonucleotide is a 5-methylcytosine.

63. (New) The method of claim 25, wherein said antisense oligonucleotide has a nucleobase sequence comprising SEQ ID NO: 23.

64. (New) The method of claim 25, wherein said antisense oligonucleotide consists of SEQ ID NO: 23.

65. (New) The method of claim 52, wherein said chimeric antisense oligonucleotide comprises a gap segment of ten 2'-deoxynucleotides positioned between 5' and 3' wing segments of five 2'-O-methoxyethyl modified nucleosides.

66. (New) The method of claim 65, wherein each internucleoside linkage of said chimeric antisense oligonucleotide is a phosphorothioate internucleoside linkage.

67. (New) The method of claim 66, wherein each cytosine of said chimeric antisense oligonucleotide is a 5-methylcytosine.

68. (New) The method of claim 30, wherein said antisense oligonucleotide has a nucleobase sequence comprising SEQ ID NO: 23.

69. (New) The method of claim 30, wherein said antisense oligonucleotide consists of SEQ ID NO: 23.

70. (New) The method of claim 25, wherein said antisense oligonucleotide consists of SEQ ID NO: 23, wherein nucleotides 1-5 and 16-20 are 2'-O-methoxyethyl nucleotides, wherein

nucleotides 6-15 are 2'-deoxynucleotides, and wherein each cytosine is a 5-methylcytosine.

71. (New) The method of claim 30, wherein said antisense oligonucleotide consists of SEQ ID NO: 23, wherein nucleotides 1-5 and 16-20 are 2'-O-methoxyethyl nucleotides, wherein nucleotides 6-15 are 2'-deoxynucleotides, and wherein each cytosine is a 5-methylcytosine.